Validated programmed cell death ligand 1 immunohistochemistry assays (E1L3N and <scp>SP</scp>142) reveal similar immune cell staining patterns in melanoma when using the same sensitive detection system
Kelly Schats(University of Antwerp), Mark Kockx(HistoGeneX (Belgium))
Cited by 39
Related Papers
<i>RAS</i> Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
|New England Journal of Medicine|2012|1k
Performance of PD-L1 immunohistochemistry (IHC) assays in unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC): Post-hoc analysis of IMpassion130
|Annals of Oncology|2019|115
Baseline biomarkers correlated with outcome in advanced melanoma treated with pembrolizumab monotherapy.
|Journal of Clinical Oncology|2020|3
The early transformation of the human saphenous vein graft. Symposium Experimenteel Onderzoek Heelkundige Specialismen, Groningen, 29/11/1991
|Ghent University Academic Bibliography (Ghent University)|1991|0